Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (81-90 of 274) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Aurora kinases as anticancer drug targetsOliver Gautschi, Jim Heighway, Philip C Mack, et al.
Archives of Internal Medicine|July 30, 2008
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisitedKaren G Chee, Danh V Nguyen, Monica Brown, et al.
European Urology Focus|May 20, 2019
Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaHyung L Kim, Eddie Mayerson, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaPhilip C Mack, David R Gandara, Alvin H Lau, et al.
Clinical Lung Cancer|October 28, 2005
Bortezomib-based combinations in the treatment of non-small-cell lung cancerAngela M Davies, Primo N Lara, Philip C Mack, et al.
Clinical Lung Cancer|October 28, 2005
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applicationsPrimo N Lara, Richard J Bold, Philip C Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosisRuth L Vinall, Kimberley Hwa, Paramita Ghosh, et al.
Investigational New Drugs|October 22, 2011
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumorsThomas J Semrad, Courtney Eddings, Chong-Xian Pan, et al.
Cancer|April 22, 2020
Germline and somatic DNA repair gene alterations in prostate cancerMarc A Dall'Era, John D McPherson, Allen C Gao, et al.
Clinical Genitourinary Cancer|September 1, 2018
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I StudyMamta Parikh, Chong-Xian Pan, Laurel A Beckett, et al.
Pageof 28

Showing results (81-90 of 274) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Aurora kinases as anticancer drug targetsOliver Gautschi, Jim Heighway, Philip C Mack, et al.
Archives of Internal Medicine|July 30, 2008
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisitedKaren G Chee, Danh V Nguyen, Monica Brown, et al.
European Urology Focus|May 20, 2019
Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaHyung L Kim, Eddie Mayerson, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|May 2, 2003
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaPhilip C Mack, David R Gandara, Alvin H Lau, et al.
Clinical Lung Cancer|October 28, 2005
Bortezomib-based combinations in the treatment of non-small-cell lung cancerAngela M Davies, Primo N Lara, Philip C Mack, et al.
Clinical Lung Cancer|October 28, 2005
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applicationsPrimo N Lara, Richard J Bold, Philip C Mack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosisRuth L Vinall, Kimberley Hwa, Paramita Ghosh, et al.
Investigational New Drugs|October 22, 2011
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumorsThomas J Semrad, Courtney Eddings, Chong-Xian Pan, et al.
Cancer|April 22, 2020
Germline and somatic DNA repair gene alterations in prostate cancerMarc A Dall'Era, John D McPherson, Allen C Gao, et al.
Clinical Genitourinary Cancer|September 1, 2018
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I StudyMamta Parikh, Chong-Xian Pan, Laurel A Beckett, et al.
Pageof 28